TFF Pharmaceuticals Announces First Dosing of Asthma Patients with Voriconazole Inhalation Powder in a Phase 1b Clinical Trial

~ Phase 1b Dosing of Voriconazole Inhalation Powder in asthma patients to evaluate safe dosing in patients with hyperreactive airways for direct-to-lung delivery of voriconazole for the treatment or prevention of Invasive Pulmonary Aspergillosis (IPA) ~ Asthma patients with hyperreactive airways represent a large proportion of patients with IPA

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here